MAP2K7 and neoplasm: Demonstrated pharmacodynamic effects of MEK inhibition with TAK-733 include decreases in phosphorylated ERK (pERK) [26], as seen in both sensitive and resistant melanoma cell lines and in tumor-bearing mice; elevated TAK-733 tumor concentrations were shown to correspond approximately with pERK reductions [25].